Citations

Clear

1792 citation(s) found for "Stephanie".

Telepresence-Assisted Robotic Common Bile Duct Exploration Using the da Vinci 5 Platform: A Novel Application of Real-Time Intraoperative Telementoring
Abutaka, Ahmad, Heller, Stephanie, Heller, Stephanie F.

Mayo Clinic

No container title available | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10260347/v1 Get It

Abstract Background Single-stage management of choledocholithiasis with intraoperative cholangiography (IOC) and concomitant common bile duct exploration (CBDE) is supported by reduced length of stay, fewer anesthetic events, and high stone-clearance rates. However, broad adoption is limited by surgeon experience and the technical demands of transcystic exploration. The fourth-generation da Vinci 5 (DV5) surgical platform (Intuitive Surgical, Sunnyvale, CA) integrates a native Telepresence module that enables a remote expert to view the operative field and the surgeon console feed in real time and to communicate with the operating surgeon through bidirectional audio and video. We describe what we believe to be the first reported use of DV5 Telepresence to assist intraoperative decision-making and execution during robotic CBDE for choledocholithiasis discovered on IOC. Methods A surgeon with early experience in common bile duct exploration while performing a robotic cholecystectomy with routine fluoroscopic IOC encountered a filling defect at the distal common bile duct consistent with an obstructing stone. A DV5 Telepresence session was activated, connecting an experienced surgeon in common bile duct exploration. The picture-in-picture (PiP) feature on the surgeon console displayed the intraoperative view and the live fluoroscopic image simultaneously, allowing both surgeons to review the cholangiogram in real time. Verbal-only guidance was provided through bidirectional audio while the operating surgeon performed transcystic flushing, balloon sweep, and sphincteroplasty. Results Total Telepresence connection time was 19 minutes. Complete duct clearance was achieved during the index operation, confirmed by completion cholangiogram. The patient was discharged from the post-anesthesia care unit with no complications. The PiP feature was identified as the technical enabler that allowed simultaneous interpretation of the cholangiogram and operative anatomy without exiting the console or duplicating monitors. Conclusions Native robotic Telepresence on the DV5 is feasible, safe, and clinically useful for time-sensitive intraoperative consultation during CBDE. By collapsing the latency between identification of choledocholithiasis and expert-guided definitive management, this approach may broaden access to single-stage biliary clearance for surgeons earlier in their learning curve and warrants prospective evaluation. This feature may allow for surgical advice/mentoring in a variety of settings/cases.
Outcomes after 7/8 and
Jiménez, Antonio , Stanek, Joseph, Logan, Brent R, Leckrone, Erin , Stefanski, Heather E., Auletta, Jeffery J., Spellman, Stephen R., Malmberg, Craig, Askar, Medhat, Cusatis, Rachel , Shaffer, Brian C., Modi, Dipenkumar , Khimani, Farhad, Gooptu, Mahasweta, Bo‐Subait, Stephanie, Bolaños-Meade, Javier, Rao, Uttam, Milner, Jordan , Jamieson, Katarzyna , Carrum, George, Kosuri, Satyajit, Cook, Rachel J., Clara, Joseph , Loren, Alison W., Arai, Sally , Choi, Sung Won , Shaw, Bronwen E., Jimenez Jimenez, Antonio Martin , Cusatis, Rachel N , Hamadani, Mehdi , Maiers, Martin , Milner, Jordan , Abboud, Ramzi , Dholaria, Bhagirathbhai R , Hogan, William J , Reshef, Ran , Ballen, Karen , Larkin, Karilyn , Arai, Sally , Qayed, Muna , Choi, Sung Won , Broglie, Larisa A , Devine, Steven , Al Malki, Monzr M , Stanek, Joseph , Logan, Brent R. , Stefanski, Heather E. , Auletta, Jeffery J. , Spellman, Stephen R. , Malmberg, Craig, Askar, Medhat , Shaffer, Brian C. , Khimani, Farhad , Gooptu, Mahasweta , Hamadani, Mehdi , Maiers, Martin , Bolaños‐Meade, Javier , Dholaria, Bhagirathbhai , Hogan, William J. , Reshef, Ran , Cook, Rachel J. , Loren, Alison W. , Broglie, Larisa , Shaw, Bronwen E. , Devine, Steven M. , Malki, Monzr M. Al

Mayo Clinic

Blood Advances | August 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026021081 | PMID 42616616 Get It

ACCESS is a prospective, multicenter phase II trial evaluating peripheral blood stem cell (PBSC) transplantation using 4-7/8 HLA-mismatched unrelated donors (MMUD) with post-transplant cyclophosphamide (PTCy), tacrolimus, and mycophenolate. Adults undergoing first HCT with myeloablative (MAC) or reduced-intensity/nonmyeloablative (RIC/NMA) conditioning were enrolled, with donors aged 18-35 years and matched at 4/8-7/8 HLA loci by high-resolution typing. This expanded analysis includes all enrolled adult PBSC recipients, including the protocol-specified RIC/NMA cohort expansion, to improve precision of outcome estimates and provide descriptive analyses by HLA match level. Among 268 adults, 183 received 7/8 and 85 received <7/8 MMUD grafts; 82.4% of the <7/8 cohort received 6/8 grafts. Median follow-up among survivors was 11.9 months. At 1-year, overall survival was 78.6% (95% CI, 71.9-83.9) in the 7/8 cohort and 85.6% (95% CI, 76.0-91.5) in the <7/8 cohort. One-year relapse, non-relapse mortality, and GVHD-free relapse-free survival were 17.1%, 13.7%, and 51.1% versus 22.8%, 8.4%, and 54.6%, respectively. The cumulative incidence of grade II-IV and grade III-IV acute GVHD by day 100 was 36.6% and 7.7% in the 7/8 cohort versus 28.3% and 5.9% in the <7/8 cohort. Moderate-to-severe chronic GVHD at 1 year was 11.3% versus 7.7%, respectively. Among adult ACCESS recipients treated on a uniform young-donor PBSC/PTCy platform, short-term outcomes with predominantly 6/8 MMUD transplantation were encouraging. Because donor match level was not prospectively assigned and between-group comparisons were exploratory, these findings are descriptive and should not be interpreted as establishing equivalence with 7/8 MMUD transplantation. (Registered as NCT04904588 at CT.gov)
Validation of the Semi-Quantitative MRI (SQ-MRI) Score as a Biomarker for Non-Calcific Chronic Pancreatitis in a Multicenter Cohort
Tirkes, Temel, Chang, Stephanie T., Mawad, Kareem , Shah, Zarine K. , Venkatesh, Sudhakar K., Wachsman, Ashley, Li, Liang, Li, Shuang, Easler, Jeffrey, Fogel, Evan L. , Forsmark, Christopher E. , Hart, Phil A., Pandol, Stephen J., Park, Walter G., Topazian, Mark, Trikudanathan, Guru, Vege, Santhi Swaroop, Conwell, Darwin L., Yadav, Dhiraj, Tirkes, Temel , Dasyam, Anil K. , Spilseth, Benjamin , Takahashi, Naoki , Venkatesh, Sudhakar K. , Easler, Jeffrey J. , Forsmark, Chris E. , Hart, Phil A. , Pandol, Stephen J , Park, Walter G., Trikudanathan, Guru , Van Den Eeden, Stephen K , Vege, Santhi Swaroop , Conwell, Darwin L. , Yadav, Dhiraj

Mayo Clinic

No container title available | August 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10504233/v1 Get It

Abstract Purpose Validate the semiquantitative (SQ)-MRI score for chronic pancreatitis (CP) diagnosis in an independent, multicenter cohort. Methods We analyzed MRIs performed at baseline in 337 participants with acute (AP) or recurrent AP (RAP) and 67 with non-calcific chronic pancreatitis (NCCP) enrolled in the PROCEED study from 6/2017 to 3/2023. MRIs were performed at multiple clinical centers using site-specific clinical protocols and a variety of MRI vendors to evaluate the SQ-MRI score in a real-world setting. The SQ-MRI score was calculated using the T1 signal intensity ratio of the pancreas to the spleen (T1 score), arteriovenous enhancement ratio (AVR), and pancreatic body diameter (PBD). We adjusted for confounding by participant characteristics via propensity score weighting. Results Median AVR was higher in AP/RAP (1.18, IQR: 0.97–1.44) than in the NCCP group (1.03, IQR: 0.78–1.22, p = 0.007). Pancreatic body diameters were larger in AP/RAP than in the NCCP group − 7–14 mm (10% vs 25%), 14–20 mm (40% vs 54%), and > 20 mm (50% vs 21%), respectively ( p < 0.01). Median T1 score was higher in AP/RAP (1.18, IQR: 0.96–1.40) than in the NCCP group (1.04, IQR: 0.86–1.32, p = 0.10). Median SQ-MRI score in the AP/RAP group was significantly lower, 1.91 (IQR: 0.97, 2.95), than in the NCCP group, 2.74 (IQR: 2.04–4.03) ( p < 0.001). The propensity score-adjusted AUC for SQ-MRI to distinguish AP/RAP from NCCP was 0.64, which was higher than for individual parameters. Conclusion We have validated the SQ-MRI score in a multicenter cohort using an independent, real-world MRI dataset.
Cold and Room-Temperature Platelets in Cardiac Surgery
Spinella, Philip C., Zantek, Nicole D., Nicolson, Susan C., Khanna, Ashish K., Boisen, Michael L., Williams, Tiffany M. , Monteleone, Matthew, Pavey, Warren, Smith, Bradford B., Ahmed, M. Iqbal, Jeng, Eric, Flynn, B S, Joshi, Ravi V. , Preuss, James , Goswami, Dheeraj, Lewis, Choy, Tint, Hlaing , Kwak, Jenny , Sodha, Neel, Simon, Eric R. , Van, Philbert Y., Greilich, Philip E. , Booth, Frank V. McL., Carter, Camille, Keegan, Anastazia , Cap, Andrew P., Matuk, James, McGlothlin, Anna, Berry, Nicholas , Lewis, Roger , Steiner, Marie E., Group, CHIPS Investigator, Hu, Paula, Hawkins, Jaleah, Jobes, David R. , Fadeyi, Emmanuel A. , Reynolds, Abigail M.A., Bell, Carter G., Gandhi, Manish J., Montonye, Beth, Serna-Gallegos, Derek, Sultan, Ibrahim, Kinney, Stephanie , Molony, Kathleen, Hensch, Lisa, Resheidat, Ashraf, Malivers, Martine, Hahn, Rebbecca, Viellez, Annette Le, Pepperell, Dominic , Lu, Qun, Downey, Frank, Haeger, Kayla N., Baltagi, Sirine , Jaquiss, Robert D.B., Noland, Daniel K., Cole, Regina, Duffin, Aspen, Scott, John P., Zeng, Long, Ballew, Angie, Webb, Christopher, Jessen, Michael, Hopson, Erryn, Mickle, Peri, Kavanagh, Simon, Matzelle, Shannon, Mennie, Colleen, Davenport, Robertson, Chlebeck, Therese, Zenk, Emmy, Lotz, Daniel T., Choi, Warren , Hobbs, Rhonda, Baptise, Amanda, DeChristopher, Phillip, Schoenecker, Nancy, Rodheim, Dianna, Connor, Joseph, Griese, Daniel J., McGuire, Erin, VanSandt, Mandy, Sera, Valerie, O’Donovan, Justine , Marks, Denese, Johnson, Lacey, Viele, Kert , Cholette, Jill M., Selke, Frank, Silverman, Toby, Shea, Susan, Yazer, Mark, Young, P. J., Ness, Paul Van, Dean, J. Michael, Shaz, Beth, Stubbs, James, Klompas, Allan M. , Spinella, Philip C. , Zantek, Nicole D. , VanBuren, John M. , Nicolson, Susan Craig , Khanna, Ashish K. , Boisen, Michael L , Monteleone, Matthew P., Bashir, Dalia A. , Pavey, Warren , Niebler, Robert A. , Jeng, Eric I-Hun , Goswami, Dheeraj , Yamada, Chisa , Lewis, Choy R., Cohn, Claudia S. , Sodha, Neel R. , Cap, Andrew , Matuk, James , Smith, Mark M. , Montonye, Beth L., Kaplan, Alesia , Kinney, Stephanie , Resheidat, Ashraf M., Downey, Francis X. , Ballew, Angie , Matzelle, Shannon A, Crowe, Liz , DeChristopher, Phillip J., Griese, Daniel, Sera, Valerie, Marks, Denese C. , Johnson, Lacey , Cholette, Jill M., Levy, Jerrold H. , Silverman, Toby , Yazer, Mark H. , Strandenes, Geir , Shaz, Beth H. , Stubbs, James R.

Mayo Clinic

JAMA | August 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jama.2026.13328 | PMID 42606886 Get It

Importance Patients undergoing cardiac surgery with cardiopulmonary bypass often require platelet transfusions for bleeding. Platelets are routinely stored at room temperature (20-24 °C) for up to 5 to 7 days; however, cold storage (1-6 °C) may allow for increased storage duration without loss of hemostatic function. Objective To determine the maximum cold-storage duration, up to 21 days, for which cold-stored platelets (CSPs) are noninferior or superior in hemostatic efficacy to room-temperature platelets (RTPs) when transfused in actively bleeding patients undergoing cardiac surgery with cardiopulmonary bypass. Design, Setting, and Participants A phase 3, multicenter, randomized, partially blinded, adaptive, noninferiority, storage duration–ranging trial conducted in pediatric and adult patients undergoing cardiac surgery with planned cardiopulmonary bypass at 27 sites in the US and Australia from December 2021 to March 2025. Statistical analysis was conducted from September 9 to October 3, 2025. Intervention Patients were randomized 2:1 to receive CSPs with a maximum of 21 days of storage vs RTPs with a maximum of 7 days of storage. Main Outcomes and Measures The primary outcome was a hemostatic efficacy score with values ranging from 1 to 5 and higher values indicating greater bleeding. The noninferiority margin was 1 point. The success criterion was met if at least 1 cold-storage duration of 7 days or more had a posterior probability of noninferiority of at least 97.5%. The secondary outcome was 24-hour chest tube output. Results Of the 1000 patients who underwent platelet transfusion, 989 were included in the primary analysis (650 CSPs and 339 RTPs). The cohort had a mean (SD) age of 42.1 (30.1) years and 67.8% were male. CSPs were noninferior to RTPs for the primary outcome, with a probability of greater than 99.9% for all cold-storage durations. Pooled across storage durations, CSPs had a mean difference from RTPs of 0.09 (95% credible interval, −0.06 to 0.23). Median (IQR) chest tube output at 24 hours (8.9 mL/kg [5.2-15.4] for CSPs vs 8.4 mL/kg [5.5-15.9] for RTPs; difference in medians, 0.4 [95% CI, −1.0 to 1.5]) was not statistically different between study groups. In a post hoc analysis, as all storage durations were noninferior, considering the CSPs as a single group, the hemostatic efficacy score was similar between both groups: mean (SD) of 3.08 (1.15) CSPs vs 2.99 (1.10) RTPs. There were no differences in venous or arterial thrombotic events, transfusion-associated adverse events, acute respiratory distress syndrome, kidney failure, septic shock, and mortality between the study groups, except for increased reexploration rates in the CSP group. Conclusions and Relevance For patients undergoing cardiac surgery, CSPs stored up to 21 days are noninferior to RTPs for the control of active surgical bleeding. Use of CSPs may allow for increased availability of platelets by reducing wastage and shortages and may allow for incorporation of platelets into inventory at locations where platelets cannot be maintained due to the 5- to 7-day shelf life of RTPs. Trial Registration ClinicalTrials.gov Identifier: NCT04834414
One Week of Pre-Program Actigraphy Identifies Dropout Risk in Home-Based Pulmonary Rehabilitation for COPD
Grady, Michelle, Zawada, Stephanie, Benzo, Roberto P. , Fortune, Emma , Grady, Michelle , Faust, Louis , Winham, Stacey J.

Mayo Clinic

2026 IEEE 14th International Conference on Healthcare Informatics (ICHI) | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: 250-255

10.1109/ichi69079.2026.00041 Get It

Bone mineral density in women with functional hypothalamic amenorrhea compared to eumenorrheic controls and recently menopausal women
Safwan, Nancy , Castaneda, Regina, Uddenberg, Erin R, Andrade, Maria D. Hurtado, Maughan, Jenna , Saadedine, Mariam , Berga, Sarah L. , Pisarska, Margareta D. , Merz, C. Noel Bairey, Hurtado Andrade, Maria D, Castaneda, Regina , Andrade, Maria D. Hurtado, Faubion, Stephanie S. , Merz, C. Noel Bairey , Shufelt, Chrisandra

Mayo Clinic

Frontiers in Endocrinology | August 4, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fendo.2026.1897514 | PMID 42614126 Get It

Introduction Functional hypothalamic amenorrhea (FHA) accounts for 30% of secondary amenorrhea and is characterized by hypothalamic hypercortisolemia, hypothalamic hypothyroidism, and anovulation with hypoestrogenemia due to disrupted GnRH drive. While FHA is associated with decreased bone mineralization; it remains unclear how bone health compares to menopausal women, who also experience bone loss. This study compared dual-energy x-ray absorptiometry (DXA) bone health parameters among women with FHA, eumenorrheic controls, and recently menopausal women. It also examined the impact of prior combined oral contraceptive (COC) use on bone mineral density (BMD) in women with FHA. Methods This cross-sectional study included 20 women with FHA, 9 eumenorrheic controls, and 12 recently menopausal women who underwent hip and spine DXA. None of the participants were taking hormone therapy. FHA was defined as ≥3 months of amenorrhea, estradiol &lt;50 pg/ml, FSH and LH &lt;10 mIU/L, excluding other etiologies. DXA bone parameters were measured using Lunar iDXA (GE) including BMD from lumbar spine (L1-L4) and hip. Results By design, age differed significantly across groups (p &lt; 0.0001), with median ages of 27.8 years [23.4, 34.1] in women with FHA, 29.6 years [28.3, 32.4] in eumenorrheic controls, and 55.3 years [53.5, 56.6] in recently menopausal women. There were no significant differences in weight or BMI across groups. Significant differences were observed at all measured skeletal sites, including all lumbar spine levels, femur neck, total femur, and total BMD (all p &lt; 0.05). Pairwise comparisons revealed that lumbar spine BMD was significantly lower in FHA compared to eumenorrheic controls (p = 0.04), while FHA and menopausal women did not significantly differ from each other (p = 0.07). Among FHA women with prior COC use, L1–4 BMD was not significantly different from controls (p = 0.19). Conclusions Lumbar spine BMD in young women with FHA was comparable to that of recently menopausal women, highlighting the profound skeletal impact of chronic estrogen deficiency. Prior COC use may partially attenuate FHA-associated bone loss, though larger studies are needed to confirm this observation. Future studies should explore whether skeletal outcomes vary by FHA etiology and the potential role of COC duration in preserving BMD.
A Pediatric Resident Physician Coaching Program With Faculty Retreat Developed in Partnership With a Master Certified Coach
Fashina, Oluwatomini, Thorvilson, Megan J. , Mavis, Stephanie C. , Thorn, Patti M. , Pittock, Siobhán T. , Munger, Kayla, McKone, Justin , Raevsky, Emily, Johnson, Katie L. , Thorvilson, Megan , Mavis, Stephanie , Pittock, Siobhan , Munger, Kayla

Mayo Clinic

MedEdPORTAL | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.11624 | PMID 42539593 Get It

Psychological symptoms during perimenopause: a global perspective
Hedges, Mary S. , Martin, Yella , Castaneda, Regina , Karam, Jana , Zhaunova, Liudmila , Faubion, Stephanie S. , Shufelt, Chrisandra , Cunningham, Adam C , Hewings-Martin, Yella , Castaneda, Regina , Karam, Jana , Zhaunova, Liudmila , Faubion, Stephanie S , Shufelt, Chrisandra L , Hedges, Mary S , Cunningham, Adam

Mayo Clinic

Menopause | July 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/gme.0000000000002872 | PMID 42517353 Get It

Objectives: Psychological health changes are known to occur during perimenopause, but the extent to which these differ from premenopause remains unclear. This study aimed to assess psychological symptoms during perimenopause compared with premenopause and evaluate differences by country. Methods: Flo app users aged 35 years or above not taking hormonal contraception or hormone therapy were included. The psychological domain of the Menopause Rating Scale (range 0-16) and symptoms within this domain of depressive mood, irritability, anxiety, and exhaustion (range 0-4 each) were evaluated. Participants in perimenopause were compared with those in premenopause (self-reported not in perimenopause or postmenopause). Results: A total of 7,975 women were included, with 2,353 in perimenopause (mean age 45 years [SD±4.5]) and 5,622 in premenopause (39 y [SD±4.0]). Psychological Menopause Rating Scale scores in the perimenopause group were significantly higher (7.3 [SD±3.56]) than in the premenopause group (4.8 [SD±3.56]; P <0.001). The individual symptoms of depressive mood, irritability, anxiety, and exhaustion were also higher in the perimenopause group ( P <0.001, for all respectively), with the largest difference being exhaustion. These findings remained after adjusting for known confounders, including an existing diagnosis of anxiety or depression. Geographic analysis included 20 countries across 6 continents, with significant differences identified between countries for the overall psychological symptom domain score and all individual symptoms. Conclusion: Significantly greater psychological symptom burden was identified in the perimenopause group compared with the premenopause group, with the greatest difference noted for the individual symptom of exhaustion. Differences in symptom burden were also identified by country.
Weight loss interventions and sexual function in midlife women: the emerging role of glucagon-like peptide-1 receptor agonists
Castaneda, Regina , Sepulveda-Gonzalez, Diego , Andrade, Maria D. Hurtado, Shufelt, Chrisandra L., Faubion, Stephanie S., Sepulveda, Diego, Hurtado Andrade, Maria D, Castaneda, Regina , Andrade, Maria D. Hurtado, Shufelt, Chrisandra , Faubion, Stephanie S. , Sepulveda, Diego

Mayo Clinic

Menopause | July 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/gme.0000000000002854 | PMID 42517362 Get It

Importance and Objective: Sexual health is a multidimensional aspect of women’s well-being. It is particularly vulnerable during midlife, when the physiological and psychosocial changes of the menopause transition intersect with the growing burden of obesity. Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as highly effective pharmacologic treatments for obesity, yet their effects on female sexual function remain largely uncharacterized. This review aims to discuss the interplay among obesity, midlife, obesity treatments, and female sexual health, with a focused synthesis of available evidence on GLP-1–based therapies and sexual outcomes in women. Methods: This narrative review synthesizes preclinical studies, case reports, observational data, and clinical trials identified through PubMed searches from inception through March 2026, examining female sexual function in the context of obesity, the menopause transition, obesity treatments, and GLP-1 receptor agonist therapy. Discussion and Conclusion: Obesity impairs female sexual function through hormonal, vascular, and psychosocial mechanisms. Accordingly, lifestyle interventions and bariatric surgery have demonstrated meaningful improvements in sexual function. In contrast, GLP-1 receptor agonists, despite conferring substantial weight loss and favorable metabolic effects, may paradoxically suppress sexual desire and arousal through central neuroendocrine mechanisms, including the modulation of dopaminergic reward and serotonergic signaling. While emerging case reports and preclinical data support this concern, systematic clinical evidence remains limited, highlighting the need for prospective studies with longitudinal sexual function endpoints. In this context, clinicians should proactively assess sexual function before and during GLP-1 therapy using validated instruments and integrate sexual health into comprehensive obesity care for midlife women.